OUTLOOK THERAPEUTICS INC (OTLK)

US69012T3059 - Common Stock

8.2  +0.11 (+1.36%)

After market: 8.2 0 (0%)

Fundamental Rating

0

OTLK gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. Both the profitability and financial health of OTLK have multiple concerns. OTLK does not seem to be growing, but still is valued expensively.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

OTLK had negative earnings in the past year.
In the past year OTLK has reported a negative cash flow from operations.
OTLK had negative earnings in each of the past 5 years.
In the past 5 years OTLK always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of OTLK (-237.49%) is worse than 91.27% of its industry peers.
Industry RankSector Rank
ROA -237.49%
ROE N/A
ROIC N/A
ROA(3y)-215.72%
ROA(5y)-221.03%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OTLK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for OTLK has been increased compared to 1 year ago.
The number of shares outstanding for OTLK has been increased compared to 5 years ago.
OTLK has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -37.34, we must say that OTLK is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -37.34, OTLK is doing worse than 92.47% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -37.34
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

OTLK has a Current Ratio of 0.44. This is a bad value and indicates that OTLK is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.44, OTLK is doing worse than 95.89% of the companies in the same industry.
OTLK has a Quick Ratio of 0.44. This is a bad value and indicates that OTLK is not financially healthy enough and could expect problems in meeting its short term obligations.
OTLK has a Quick ratio of 0.44. This is amonst the worse of the industry: OTLK underperforms 95.55% of its industry peers.
Industry RankSector Rank
Current Ratio 0.44
Quick Ratio 0.44

More info and screens

1

3. Growth

3.1 Past

OTLK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -988.89%.
EPS 1Y (TTM)-988.89%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-900%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, OTLK will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.02% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-23.39%
EPS Next 2Y11.34%
EPS Next 3Y24.71%
EPS Next 5Y18.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OTLK. In the last year negative earnings were reported.
Also next year OTLK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

OTLK's earnings are expected to grow with 24.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.34%
EPS Next 3Y24.71%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OTLK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OUTLOOK THERAPEUTICS INC

NASDAQ:OTLK (4/23/2024, 7:17:37 PM)

After market: 8.2 0 (0%)

8.2

+0.11 (+1.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap176.96M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -237.49%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.44
Quick Ratio 0.44
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-988.89%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-23.39%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y